Safety and efficacy of combination of temozolomide and pazopanib in patients with advanced pancreatic neuroendocrine tumors (PNET)

Autor:	Alfred Rademaker, Jordan Berlin, Mark M. Zalupski, Mary F. Mulcahy, Sheetal Mehta Kircher, Al B. Benson, Crystal S. Denlinger, E. Gabriela Chiorean, Vaibhav Sahai, Halla Sayed Nimeiri, Steven J. Cohen, Sachin Gopalkrishn Pai
Rok vydání:	2016
Předmět:	Cancer Research Temozolomide medicine.drug_class business.industry Angiogenesis Phases of clinical research Neuroendocrine tumors medicine.disease Tyrosine-kinase inhibitor Pazopanib Oncology embryonic structures cardiovascular system Cancer research medicine In patient business medicine.drug
Zdroj:	Journal of Clinical Oncology. 34:e15662-e15662
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2016.34.15_suppl.e15662
Popis:	e15662Background: Pazopanib (Pazo) is an angiogenesis tyrosine kinase inhibitor(TKI) targeting VEGFR-1, -2, and -3; PDGFR-α, -β; and c-Kit. Pazo has shown activity in a single arm phase II study in...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::66e0a3444349f2530e72ef407db56c4e https://doi.org/10.1200/jco.2016.34.15_suppl.e15662 Zobrazit plný text záznamu